Béatrice Cameron

This inventor holds 17 USPTO granted patents and 11 published patent applications and 13 EPO patents. Top assignees: Sanofi, Centelion, Aventis Pharma S.a.. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Béatrice Cameron. Retrieved from https://idiyas.com/inventor/béatrice-cameron

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 11)

% Patents Active = 76.5

EPO Patents = 13 (Patent Applications = 23)

Average Co-Inventor Count = 6.3

ph-index = 3

Forward Citations = 40(Granted Patents)

Company Filing History:

Years Active: 2006-2026

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12570761 - ANTI-CEACAM5 ANTIBODIES AND USES THEREOF (2026-03-10),

2. 12227573 - Trispecific binding proteins, methods, and uses thereof (2025-02-18),

3. 11655302 - Anti-CD38 antibodies and formulations (2023-05-23),

4. 11613576 - Trispecific binding proteins, methods, and uses thereof (2023-03-28),

5. 11530268 - Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection (2022-12-20),

6. 11365261 - Anti-CD38 antibodies and methods of use (2022-06-21),

7. 11332542 - Anti-CEACAM5 antibodies and uses thereof (2022-05-17),

8. 11186649 - Anti-CD38 antibodies and methods of use (2021-11-30),

9. 10457739 - Anti-CEACAM5 antibodies and uses thereof (2019-10-29),

10. 9809653 - Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof (2017-11-07),

11. 9617345 - Anti-CEACAM5 antibodies and uses thereof (2017-04-11),

12. 9234039 - Peptide or peptide complex binding to ALPHA2 integrin and methods and uses involving the same (2016-01-12),

13. 8481487 - Modified soluble FGF receptor Fc fusions method (2013-07-09),

14. 8399636 - Purification of a triple helix formation with an immobilized obligonucleotide (2013-03-19),

15. 8017744 - Purification of a triple helix formation with an immobilized oligonucleotide (2011-09-13),

Title: Béatrice Cameron: A Pioneer in Trispecific Binding Proteins

Introduction

Béatrice Cameron, an innovative inventor based in Paris, France, has made significant contributions to the field of biopharmaceuticals, holding 16 patents to date. His work focuses on the development of advanced binding proteins and therapeutic antibodies, with implications for cancer and HIV treatment.

Latest Patents

Cameron's latest patents showcase his expertise in creating trispecific and trivalent binding proteins. One notable innovation describes binding proteins comprising four polypeptide chains that form three antigen binding sites. These proteins are designed to bind specifically to target proteins, including CD28, CD3, and various tumor-associated antigens. In certain embodiments, the binding proteins can also target HIV proteins, offering promising avenues for research and therapy. Furthermore, he has developed anti-CD38 antibodies and formulations, detailing methods for their preparation and application in clinical settings.

Career Highlights

Throughout his career, Cameron has collaborated with prominent companies in the pharmaceutical industry, including Sanofi and Centelion. His pivotal contributions to the development of novel therapeutics demonstrate a commitment to harnessing technology for healthcare advancements.

Collaborations

Cameron has worked alongside prominent researchers such as Tarik Dabdoubi and Francis Blanche, highlighting the collaborative nature of innovation in scientific research. These partnerships have facilitated knowledge sharing and the advancement of cutting-edge biotechnology.

Conclusion

Béatrice Cameron's extensive body of work and his innovative patents in binding proteins and antibodies underscore his role as a leading inventor in the biopharmaceutical field. His ongoing research continues to pave the way for new therapeutic options, making a lasting impact on the health sector.

Profile summary based on public USPTO records.